Lapatinib Stada (Lapatinib)

Lapatinib blocks the intracellular tyrosine kinase activity of HER2 (ErbB2) and EGFR (ErbB1). By preventing autophosphorylation of these receptors, it stops downstream MAPK and PI3K/AKT pathways, reducing cell proliferation and survival in tumors that rely on HER2 signaling.

The specific dose of Lapatinib is determined by the treating physician based on the patient’s clinical condition, concomitant therapies, and tolerability. Prescribers follow approved labeling and adjust the regimen as needed; patients should follow the exact instructions provided by their healthcare professional.

The safety of Lapatinib during pregnancy and lactation has not been established. It is classified as contraindicated or not recommended for use in pregnant or nursing women because potential risks to the fetus or infant cannot be ruled out. Effective contraception is advised during treatment.

To order Lapatinib Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lapatinib is an oral small‑molecule tyrosine kinase inhibitor, whereas the main alternative, trastuzumab, is a monoclonal antibody administered intravenously. Lapatinib offers the convenience of oral dosing and can be combined with capecitabine, but it may have a different safety profile, including higher rates of diarrhea and skin rash compared with trastuzumab.

Lapatinib tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Lapatinib is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals and other medications to ensure consistent absorption.

Serious risks include hepatotoxicity (elevated liver enzymes or hepatitis), cardiac dysfunction such as reduced left ventricular ejection fraction, interstitial lung disease, severe skin reactions like Stevens‑Johnson syndrome, and QT‑interval prolongation that can lead to arrhythmias. Prompt medical attention is required if any of these occur.

Lapatinib should not be used by patients with known hypersensitivity to the drug or any of its excipients, those with uncontrolled severe diarrhea, or individuals with significant cardiac disease, such as recent myocardial infarction or uncontrolled heart failure. Caution is also advised in patients with moderate to severe hepatic impairment.